Exponential Rise in Prostate-Specific Antigen (PSA) during Anti-Androgen Withdrawal Predicts PSA Flare after Docetaxel Chemotherapy in Patients with Castration-Resistant Prostate Cancer
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: To investigate the relationship between rising patterns of prostate-specific antigen (PSA) before chemotherapy and PSA flare during the early phase of chemotherapyin patients with castration-resistant prostate cancer (CRPC). Materials and Methods: This study included 55 patients with CRPC who received chemotherapy and in whom pre-treatment or post-treatment PSA levels could be serially obtained. The baseline parameters included age, performance, Gleason score, PSA level, and disease extent. PSA doubling time was calculated using the different intervals: the conventional interval from the second hormone manipulation following the nadir until anti-androgen withdrawal (PSADT1), the interval from the initial rise after anti-androgen withdrawal to the start of chemotherapy (PSADT2), and the interval from the nadir until the start of chemotherapy (PSADT3). The PSA growth patterns were analyzed using the ratio of PSADT2 to PSADT1. Results: There were two growth patterns of PSA doubling time: 22 patients (40.0%) had a steady pattern with a more prolonged PSADT2 than PSADT1, while 33 (60.0%) had an accelerating pattern with a shorter PSADT2 than PSADT1. During three cycles of chemotherapy,PSA flare occurred in 11 patients (20.0%); of these patients, 3 were among 33 (9.1%) patients with an accelerating PSA growth pattern and 8 were among 22 patients(36.4%) with a steady PSA growth pattern (p=0.019). Multivariate analysis showed that only PSA growth pattern was an independent predictor of PSA flare (p=0.034). Conclusion: An exponential rise in PSA during anti-androgen withdrawalis a significant predictor for PSA flare during chemotherapy in CRPC patients.
Abstract
Purpose: To investigate the relationship between rising patterns of prostate-specific antigen (PSA) before chemotherapy and PSA flare during the early phase of chemotherapyin patients with castration-resistant prostate cancer (CRPC). Materials and Methods: This study included 55 patients with CRPC who received chemotherapy and in whom pre-treatment or post-treatment PSA levels could be serially obtained. The baseline parameters included age, performance, Gleason score, PSA level, and disease extent. PSA doubling time was calculated using the different intervals: the conventional interval from the second hormone manipulation following the nadir until anti-androgen withdrawal (PSADT1), the interval from the initial rise after anti-androgen withdrawal to the start of chemotherapy (PSADT2), and the interval from the nadir until the start of chemotherapy (PSADT3). The PSA growth patterns were analyzed using the ratio of PSADT2 to PSADT1. Results: There were two growth patterns of PSA doubling time: 22 patients (40.0%) had a steady pattern with a more prolonged PSADT2 than PSADT1, while 33 (60.0%) had an accelerating pattern with a shorter PSADT2 than PSADT1. During three cycles of chemotherapy,PSA flare occurred in 11 patients (20.0%); of these patients, 3 were among 33 (9.1%) patients with an accelerating PSA growth pattern and 8 were among 22 patients(36.4%) with a steady PSA growth pattern (p=0.019). Multivariate analysis showed that only PSA growth pattern was an independent predictor of PSA flare (p=0.034). Conclusion: An exponential rise in PSA during anti-androgen withdrawalis a significant predictor for PSA flare during chemotherapy in CRPC patients.
참고문헌 (20)
- Jemal A, "Cancer statistics, 2007", CA Cancer J Clin, 57, pp.43~66 (2007)
- Parkin DM, "Global cancer statistics, 2002", CA Cancer J Clin, 55, pp.74~108 (2005)
- 구교철, "Unrecognized Kinetics of Serum Testosterone: Impact on Short-Term Androgen Deprivation Therapy for Prostate Cancer", Yonsei Medical Journal, 55(3), pp.570~575 (2014), 연세대학교의과대학[DOI]
- 김영민, "Role of Prostate Volume in the Early Detection of Prostate Cancer in a Cohort with Slowly Increasing Prostate Specific Antigen", Yonsei Medical Journal, 54(5), pp.1202~1206 (2013), 연세대학교의과대학[DOI]
- Debes JD, "Mechanisms of androgen-refractory prostate cancer", N Engl J Med, 351, pp.1488~1490 (2004)
- Vaishampayan U, "Update in systemic therapy of prostate cancer: improvement in quality and duration of life", Expert Rev Anticancer Ther, 8, pp.269~281 (2008)
- 정재영, "Docetaxel Chemotherapy of Korean Patients with Hormone-refractory Prostate Cancer:Comparative Analysis between 1st-line and 2nd-line Docetaxel", Yonsei Medical Journal, 49(5), pp.775~782 (2008), 연세대학교의과대학
- 홍성준, "A Prospective, Multicenter, Open-label Trial of Zoledronic Acid in Patients with Hormone Refractory Prostate Cancer", Yonsei Medical Journal, 48(6), pp.1001~1008 (2007), 연세대학교의과대학
- Armstrong AJ, "Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature", Oncologist, 14, pp.816~827 (2009)
- Tsui KH, "Prostate specific antigen gene expression in androgen insensitive prostate carcinoma subculture cell line", Anticancer Res, 28, pp.1969~1976 (2008)
- Thuret R, "The postchemotherapy PSA surge syndrome", Ann Oncol, 19, pp.1308~1311 (2008)
- Sella A, "Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer", BJU Int, 102, pp.1607~1609 (2008)
- Nelius T, "Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy", Int Urol Nephrol, 40, pp.97~104 (2008)
- Fosså SD, "Liposomal doxorubicin (Caelyx) in symptomatic androgen-independent prostate cancer (AIPC)--delayed response and flare phenomenon should be considered", Scand J Urol Nephrol, 36, pp.34~39 (2002)
- Heidenreich A, "Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma", Cancer, 101, pp.948~956 (2004)
- Olbert PJ, "Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel", Anticancer Drugs, 17, pp.993~996 (2006)
- Arlen PM, "Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time", J Urol, 179, pp.2181~2185 (2008)
- Daskivich TJ, "Prostate specific antigen doubling time calculation: not as easy as 1, 2, 4", J Urol, 176, pp.1927~1937 (2006)
- Nelius T, "PSA surge", flare-up in patients with castration-refractory prostate cancer during the initial phase of chemotherapy, 2009, pp.69, 1802~1807
- Tsui KH, "Identifying the combination of the transcriptional regulatory sequences on prostate specific antigen and human glandular kallikrein genes", J Urol, 172(5 Pt 1), pp.2029~2034 (2004)